FWBI NASDAQ

First Wave BioPharma, Inc. is a biopharmaceutical company in the clinical development phase, concentrating on the research and creation of specialized, non-systemic treatments for various gastrointestinal conditions. The company's therapeutic pipeline centers on two main compounds: 1. Niclosamide: An oral small molecule recognized for its antiviral and anti-inflammatory properties. Programs utilizing niclosamide include: FW-COV, currently undergoing Phase II trials for gastrointestinal infections caused by SARS-CoV-2. FW-UP (Phase II) and FW-UC (Phase Ib/IIa), both targeting ulcerative proctitis and ulcerative proctosigmoiditis. FW-ICI-AC, designed to treat colitis and diarrhea linked to immune checkpoint inhibitors in advanced cancer patients. FW-CD, which has successfully completed Phase I clinical trials for Crohn's disease. 2. Adrulipase: A biologic, recombinant lipase enzyme formulated as an oral, non-systemic capsule. Its purpose is to assist in the digestion of fats and other nutrients, with development focused on treating exocrine pancreatic insufficiency (EPI) in patients afflicted with cystic fibrosis and chronic pancreatitis. Originally founded in 2014, the company operated as AzurRx BioPharma, Inc. until it adopted the name First Wave BioPharma, Inc. in September 2021. The firm's headquarters are located in Boca Raton, Florida.